The Trump administration is making a significant effort to reduce the cost of weight loss drugs. Its agreement with pharmaceutical giants, announced Nov. 6, 2025, will reduce the monthly prices…
Tag: GLP-1
Potential Depression Risk Linked to Ozempic-Like Drugs
Summary: A new international study reveals a possible connection between GLP1 receptor agonists—used in drugs like Ozempic—and increased risk of depression and suicidal ideation, especially in people with low dopamine…
Ozempic and similar weight loss drugs may lower risk of 42 health conditions, but also pose risks
Several years ago, a little-known drug named Ozempic – previously used only to treat diabetes – emerged as a promising new drug for weight management. The Food and Drug Administration’s…
GLP-1 Drugs Offer Brain Benefits but May Pose Other Health Risks
Summary: A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health benefits, including…
Off-brand Ozempic, Zepbound and other weight loss products carry undisclosed risks for consumers
In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as billion-dollar annual sellers for weight loss as well as to…
No Link Found Between Ozempic and Suicide Risk
Summary: A new study has found no evidence that GLP-1 analogues, common diabetes drugs, increase the risk of suicide, self-harm, or related mental health issues. Researchers analyzed data from around…
Adjusting Proteins Increases Ozempic’s Effectiveness
Summary: Adjusting melanocortin proteins in the brain enhances the effectiveness of GLP-1 diabetes and weight-loss drugs. By inhibiting MC3R or activating MC4R, mice showed increased sensitivity to these drugs, leading…
